Fed­er­al court gives Te­va and Vi­a­tris an­oth­er chance to in­val­i­date J&J's last patent for In­ve­ga Susten­na

John­son & John­son on­ly has one last patent cov­er­ing its long-act­ing block­buster schiz­o­phre­nia drug In­ve­ga Susten­na, and now Te­va and Vi­a­tris have an­oth­er op­por­tu­ni­ty to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER